Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

BACKGROUND: Aberrant PI3K signalling is implicated in trastuzumab resistance in HER2-positive gastric cancer (GC). The role of PI3K or MEK inhibitors in sensitising HER2-positive GCs to trastuzumab or in overcoming trastuzumab resistance is unclear. METHODS: Using mass spectrometry-based genotyping...

Descripción completa

Detalles Bibliográficos
Autores principales: Mezynski, M. Janusz, Farrelly, Angela M., Cremona, Mattia, Carr, Aoife, Morgan, Clare, Workman, Julie, Armstrong, Paul, McAuley, Jennifer, Madden, Stephen, Fay, Joanna, Sheehan, Katherine M., Kay, Elaine W., Holohan, Ciara, Elamin, Yasir, Rafee, Shereen, Morris, Patrick G., Breathnach, Oscar, Grogan, Liam, Hennessy, Bryan T., Toomey, Sinead
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088633/
https://www.ncbi.nlm.nih.gov/pubmed/33933113
http://dx.doi.org/10.1186/s12967-021-02842-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088633/
https://www.ncbi.nlm.nih.gov/pubmed/33933113
http://dx.doi.org/10.1186/s12967-021-02842-1

Ejemplares similares